& Ji, Q
Diabetes Care 33(2):428433 Eguchi Y, Kitajima Y, Hyogo H, Takahashi H, Kojima M, Ono M et al (2015) Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)
Originally developed to treat type 2 diabetes under the brand name Ozempic, its dramatic weight-loss effects led the FDA to approve a higher-dose version, Wegovy , specifically for chronic weight management in 2021
Researchers also examined major adverse CV events in patient subgroups on the basis of major adverse CV event rates in the placebo group, the presence or absence of CVD, HbA1c level, trial duration, treatment dosing interval, structural homology to human GLP-1 or exendin-4, BMI, age and eGFR
Niveau : Intermdiaire avanc Cette section sadresse aux lecteurs qui souhaitent comprendre le fonctionnement de la tirzpatide au-del des explications simplifies
Lifestyle Factors Complementary strategies for best outcomes